FIELD: medicine.
SUBSTANCE: there are offered versions of human IL-13 antibodies, including based on CDR antibody BAK278D6. There is described a based composition, and also isolated nucleic acid, a host cell for preparing antibodies and versions of the method for preparing antibodies. There is disclosed application of antibodies for preparing a drug and a composition for treating various diseases mediated by IL-13 activity. Application of the invention provides antibodies neutralising IL-13.
EFFECT: applicable in medicine for preparing a vaccine.
52 cl, 32 dwg, 7 tbl, 29 ex
| Title | Year | Author | Number |
|---|---|---|---|
| PARTNERS OF SPECIFIC BINDING WITH NGF | 2006 |
|
RU2406728C2 |
| ELEMENT BOUND WITH INTERLEUKIN-4 RECEPTOR α (IL-4Rα)-173 | 2008 |
|
RU2490278C2 |
| ANTIGEN ASSOCIATED WITH RHEUMATOID ARTHRITIS | 2013 |
|
RU2649368C2 |
| COMPOUNDS | 2007 |
|
RU2466139C2 |
| ANTIBODY AGAINST IL-4R AND APPLICATION THEREOF | 2018 |
|
RU2758091C1 |
| NEUTRALIZING BINDING MOLECULES DIRECTED AGAINST INFLUENZA VIRUS, AND METHODS OF THEIR APPLICATION | 2016 |
|
RU2721706C2 |
| ANTIBODIES SPECIFIC TO BTN2 AND THEIR APPLICATIONS | 2018 |
|
RU2794996C2 |
| ANTIGENS ASSOCIATED WITH INFLAMMATORY BOWEL DISEASE | 2012 |
|
RU2612878C2 |
| ANTI-IL-1R1 BINDING MEMBERS | 2009 |
|
RU2555532C2 |
| MYOCARDIAL INFARCTION TREATMENT USING TGF-BETA ANTAGONISTS | 2011 |
|
RU2637088C2 |
